Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease

NCT03659136 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03659136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03659136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2018
Completion date
May 11, 2022
Enrollment
103 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms